Article Text

Download PDFPDF
Winter 2017 Children’s Cancer and Leukaemia Group febrile neutropenia audit
  1. Jessica Elizabeth Morgan,
  2. Bob Phillips
  1. Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK
  1. Correspondence to Dr Jessica Elizabeth Morgan, Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK; jess.morgan{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Febrile neutropenia (FN) is the most common life-threatening complication of treatment for childhood cancer.1 The UK Children’s Cancer and Leukaemia Group (CCLG) have conducted two previous national audits to assess practice against the standards described in the 2012 NICE CG151 guidelines on neutropenia sepsis.2–4 These demonstrated improvements in assessment and ongoing management of episodes of FN but variations in care persisted. In winter 2017, we conducted a further audit to assess progress. The methods were similar to previous years to allow for comparison with earlier data, though the timing changed to capture data over the winter period when units might be expected to …

View Full Text


  • Twitter @drjessmorgan

  • Contributors BP and JM designed and ran the audit. JM analysed the data and provided the first draft of the manuscript. BP provided critique of the analysis and substantially redrafted the manuscript. Both authors have approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Collaborators on behalf of the Children’s Cancer and Leukaemia Group Supportive Care Group.